Skip to main content
Equibles
EBS logo

EBS · Emergent BioSolutions Inc. · Metrics

Track EBS — free

Use EBS with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research EBS.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$6.20 -0.09 (-1.43%) At close · Oct 21
Russell 2000 member Rebalance outlook locked
Market Cap
$317.89M
Shares
51.27M
Volume · Oct 21 851.82K Avg daily vol (3M) 1.19M

EBS metrics

102 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$6.20
Market cap
$317.89M

Price action

20 metrics
Price change (1W)
-9.0%
Price change (30D)
-4.0%
Price change (3M)
-17.8%
Price change (6M)
-21.4%
Price change (YTD)
-49.1%
Price change (1Y)
-36.0%
Trailing year
Price change (5Y)
-87.4%
52-week high
$13.90
52-week low
$4.45
Change from 52-week high
-54.7%
Change from 52-week low
+41.3%
Annualized volatility
79.6%
Annualized volatility (3M)
86.5%
Beta
1.2
RSI (14D)
43.7
Price vs SMA 50
+2.2%
Price vs SMA 200
-23.9%
Avg volume (3M)
1.19M
Relative volume
1.1
Average dollar volume
$7.15M

Company

3 metrics
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Shares outstanding
51.27M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
1.0×
reciprocal yield 99.7%
EV / EBITDA
27.2×
reciprocal yield 3.7%
EV / EBIT
—
P / sales
0.4×
reciprocal yield 238.8%
P / book
0.9
reciprocal yield 105.9%
FCF yield
26.6%
TTM · current market cap
Buyback yield
11.2%
P / FCF
3.8
reciprocal yield 26.6%
P / operating cash flow
3.3
reciprocal yield 30.3%
Earnings yield
-54.8%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
11.7×
reciprocal yield 8.5%
EV / revenue historical average (3Y)
0.9×
reciprocal yield 107.0%
EV / revenue historical average (5Y)
1.0×
reciprocal yield 98.1%
EV / EBIT historical average (3Y)
10.0×
reciprocal yield 10.0%
EV / EBIT historical average (5Y)
9.3×
reciprocal yield 10.8%
EV / EBITDA historical average (3Y)
31.4×
reciprocal yield 3.2%
EV / EBITDA historical average (5Y)
27.1×
reciprocal yield 3.7%

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
11.2%
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-08-05

Profitability

9 metrics
Gross margin
—
Operating margin
-8.6%
Trailing 12 months
Net margin
-23.0%
Gross profit (TTM)
$345.80M
Operating profit (TTM)
−$66.00M
Net income (TTM)
−$176.80M
Trailing 12 months
Diluted EPS (TTM)
$-3.46
FCF margin
11.2%
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
$13.92
Gross profit per diluted share (TTM)
$6.45
Operating profit per diluted share (TTM)
$-1.36
EBITDA per diluted share (TTM)
$0.34
Net income per diluted share (TTM)
$-3.39
Operating cash flow per diluted share (TTM)
$1.77
Free cash flow per diluted share (TTM)
$1.56
Capital expenditures per diluted share (TTM)
$0.21
R&D per diluted share (TTM)
$0.81
Stock compensation per diluted share (TTM)
$0.34
Book value per share
$10.03

Growth

11 metrics
Revenue growth YoY
+66.3%
Year over year
Net income growth YoY
—
Revenue (TTM)
$770.20M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
-4.8%
Year over year · fewer shares
Revenue CAGR (3Y)
-12.7%
Revenue CAGR (5Y)
-14.0%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
-30.4%
FCF CAGR (3Y)
—
FCF CAGR (5Y)
-16.9%

Quality

14 metrics
Return on equity
-51.8%
Return on assets
-15.8%
Debt / equity
1.7
Current ratio
5.4
EBITDA (TTM)
$28.40M
Free cash flow (TTM)
$85.90M
Quick ratio
3.0
Interest coverage
-1.3
Net debt / EBITDA
15.8
Return on invested capital
—
Trailing 12 months
Net cash
−$450.00M
Latest balance sheet
Cash & equivalents
$139.70M
Total assets
$1.12B
Total debt
$589.70M

Cash flow & spend

7 metrics
Operating cash flow (TTM)
$97.70M
Capital expenditures (TTM)
$11.80M
R&D (TTM)
$45.30M
SG&A (TTM)
$181.20M
Stock compensation (TTM)
$18.90M
R&D / revenue
5.9%
Stock compensation / revenue
2.5%

Ownership (13F)

9 metrics
13F filers
197
13F filer change QoQ
+5
Institutional ownership
88.1%
Conviction holders (share of 13F filers)
0.5%
Crowding (high-turnover and private-fund holders)
29.4%
Private-fund adviser ownership
26.3%
Active holders' share change QoQ
+3.2%
Holder tenure
14.3
Price vs estimated holder cost
-1.9%

Ownership (registered funds)

1 metrics
Index-fund ownership
21.1%

Short interest

3 metrics
Short interest
18.1%
Latest settlement · 8.3 days to cover
Days to cover
8.3d
Short-squeeze score
78 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$145,792
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 1367644 CUSIP 29089Q105 13F (30d) 22 filings 22 filers Visit website Investor relations